N
N

Novartis


News

Novartis halts study of iscalimab in kidney transplant patients

ZURICH, Sept 3 (Reuters) - Novartis NOVN.S has halted a clinical trial of CFZ533 (iscalimab) in kidney transplant patients after interim data showed it was not as good as tacrolimus-based treatment in preventing organ rejection, the Swiss group said on Friday. Its study of the medicine in liver transplant continues, as do studies exploring it as a
N

Blue-chip earnings, travel stocks boost European shares

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * ASML nears record high after results * STOXX 600 Q2 profit seen rising 115% * SAP slips despite forecast lift (Updates to close) By Sruthi Shankar July 21 (Reuters) - A slew of upbeat updates from European blue-chip firms helped the region
N
S
A
G
E
F
U

Novartis weighs entry into mRNA technology, chairman tells paper

ZURICH, July 1 (Reuters) - Swiss drugmaker Novartis NOVN.S could get into the field of messenger ribonucleic acid (mRNA) technology, which has come to the fore in vaccine development during the coronavirus pandemic, Chairman Joerg Reinhardt said in a newspaper interview. In the Aargauer Zeitung interview, Reinhardt also highlighted the company's re
N

Novartis weighs entry into mRNA technology -chairman tells paper

ZURICH, July 1 (Reuters) - Swiss drugmaker Novartis NOVN.S could get into the hot field of messenger ribonucleic acid (mRNA) technology, which has come to the fore during the coronavirus pandemic, Chairman Joerg Reinhardt said in a newspaper interview. "The mRNA technology has proven to be an attractive option in this situation and of course every
N

CureVac 19 vaccine records only 48% efficacy in final trial readout

By Ludwig Burger June 30 (Reuters) - CureVac 5CV.DE said its COVID-19 vaccine was 48% effective in the final analysis of its pivotal mass trial, only marginally better than the 47% reported after an initial read-out two weeks ago. The German biotech firm said that efficacy, measured by preventing symptomatic disease, was slightly better at 53% when
B
G
N
P

CureVac may let contractors make rival vaccines if own shot fails -CEO

By Tilman Blasshofer and Ludwig Burger FRANKFURT, June 17 (Reuters) - German biotech firm CureVac 5CV.DE could allow its network of manufacturing partners to be repurposed to make vaccines developed by other companies should its own experimental shot fail, its chief executive told Reuters on Thursday. The German company saw billions of euros wiped
B
G
N
P
W

CureVac starts review process in Switzerland for 19 vaccine hopeful

ZURICH, April 19 (Reuters) - Germany's CureVac 5CV.DE filed in Switzerland for a rolling review of its COVID-19 vaccine candidate, the Swiss drugs regulator Swissmedic said on Monday, as yet another maker of shots races toward the approval finish line. Switzerland, which to date has approved COVID-19 shots from Pfizer PFE.N , Moderna MRNA.O and Joh
A
N
P

Sustainability-linked bond market to swell up to $150 bln - JPMorgan ESG DCM head

* SLB-linked bond market to grow 20-fold this year -JPM banker * Expects it to be between $120 bln and $150 bln - JPM's Ceci * SLBs allow firms to raise money for general corporate purposes * COVID-19 boosted interest in climate-linked bonds By Dhara Ranasinghe LONDON, March 22 (Reuters) - The market for bonds that are linked to companies meeting c
E
J
N
T
H

Novartis joins CureVac's vaccine contractor line-up

* Trial read-out expected early in second quarter * Other partners include Bayer, GSK, Fareva, Rentschler * Novartis site to come online in summer of 2021 * Novartis to make up to 50 mln doses this year By Ludwig Burger FRANKFURT, March 4 (Reuters) - German biotech firm CureVac 5CV.DE has enlisted Swiss pharmaceutical giant Novartis NOVN.S to help
B
G
N
W

CureVac gets vaccine production support from Novartis

FRANKFURT, March 4 (Reuters) - German biotech firm CureVac 5CV.DE has enlisted Swiss pharma giant Novartis NOVN.S to help with the production of its experimental COVID-19 vaccine. Novartis plans to manufacture the mRNA molecules that the two-shot vaccine is based on as well as "bulk drug product" for up to 50 million doses by the end of 2021 and up
N

Austria and Denmark plan vaccines with Israel to bolster slow EU supply

* Austria says faster action needed due to mutations * Denmark argues capacity needs to be increased * Other EU states have placed side orders with Russia, China * Our vaccine strategy is not unravelling - European Commission (Updates with European Commission comment, vaccination progress, companies invited to Austria talks) By Francois Murphy and
A
N
P

Bayer and Rentschler to help produce CureVac's 19 shot

* Bayer to produce 160 mln doses of CureVac vaccine in 2022 * Rentschler to make more than 100 mln doses a year * CureVac vaccine is in late-stage clinical trials BERLIN, Feb 1 (Reuters) - CureVac CVAC.O has signed up pharmaceuticals giant Bayer BAYGn.DE and contract drugmaker Rentschler to help to produce its experimental COVID-19 vaccine, joining
A
B
G
N
P
S

Swiss drugmaker Novartis to help make Pfizer-BioNTech 19 vaccine

ZURICH, Jan 29 (Reuters) - Swiss drugmaker Novartis NOVN.S has signed an initial agreement to fill vials for Pfizer PFE.N and BioNTech's 22UAy.DE COVID-19 vaccine, a move aimed at helping boost production as supplies fall behind demand. Subject to reaching a final deal, Novartis plans to start production in the second quarter of 2021, the Basel-bas
A
N
P
S

Novartis's regulatory delays add to pandemic sales hit

* Zolgensma, Leqvio face regulatory delays * Q4 sales, profit missed analyst forecasts * CEO sees COVID-19 affecting business through H1 (Recasts to focus on regulatory hurdles) By John Miller ZURICH, Jan 26 (Reuters) - Switzerland's Novartis NOVN.S said delays of two blockbuster hopefuls - heart drug Leqvio that cost it $10 billion and $2.1 millio
N

How does AstraZeneca's vaccine compare with Pfizer-BioNTech?

(Updates paragraphs 4-7 to add context with comment from University of Oxford in 8th paragraph) By John Miller ZURICH, Dec 30 (Reuters) - Britain on Wednesday became the first country to approve AstraZeneca AZN.L and Oxford University's home-grown UK COVID-19 vaccine, adding an easy-to-manage shot to the arsenal of a nation desperate for pandemic r
A
N
P

How does AstraZeneca's vaccine compare with Pfizer-BioNTech?

By John Miller ZURICH, Dec 30 (Reuters) - Britain on Wednesday became the first country to approve AstraZeneca AZN.L and Oxford University's home-grown UK COVID-19 vaccine, adding an easy-to-manage shot to the arsenal of a nation desperate for pandemic relief. Even so, scientists - and regulators in Europe, following the Brexit divorce - are scepti
A
N
P

Trial fails of ruxolitinib in 19 complications- Novartis

ZURICH, Dec 14 (Reuters) - Novartis NOVN.S said a late-stage clinical trial of ruxolitinib on top of standard therapy showed no significant reduction in severe complications of COVID-19, including death, respiratory failure requiring mechanical ventilation or admission to the intensive care unit. The RUXCOVID trial also did not show relevant benefi
I
N

Trial fails of ruxolitinib in 19 - Novartis

ZURICH, Dec 14 (Reuters) - Novartis NOVN.S said a late-stage clinical trial of ruxolitinib on top of standard therapy showed no significant reduction in severe complications of COVID-19, including death, respiratory failure requiring mechanical ventilation or admission to the intensive care unit. The trial also did not show relevant benefit for oth
I
N

Business rights or human rights? Swiss vote shines spotlight on companies

* Swiss vote on Nov. 29 on 'Responsible Business Initiative' * Proposals aim to make Swiss companies more accountable * Campaign has polarized the business-friendly country * Swiss multinationals say initiative proposals go too far By Brenna Hughes Neghaiwi ZURICH, Nov 26 (Reuters) - A billboard of a runny-nosed, dour-faced girl framed by Glencore'
C
G
N
N
R

How two companies sprinted ahead in extraordinary race for a COVID vaccine

(Repeat to include RICs) By Michael Erman and Julie Steenhuysen Nov 17 (Reuters) - Just as the novel coronavirus was gaining a foothold in the United States in mid-March, Pfizer Inc PFE.N Chief Executive Albert Bourla called on his top vaccine scientists and laid out a clear mission: “He basically said, ‘Your mandate is to get this vaccine made
N



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.